InChI=1S/C26H45NO20/c1-6-12(32)16(36)18(38)24(41-6)47-22-21(46-25-19(39)17(37)13(33)8(3-28)43-25)15(35)10(5-30)44-26(22)45-20-11(27-7(2)31)23(40)42-9(4-29)14(20)34/h6,8-26,28-30,32-40H,3-5H2,1-2H3,(H,27,31)/t6-,8+,9+,10+,11+,12+,13-,14+,15-,16+,17-,18-,19+,20+,21-,22+,23+,24-,25+,26-/m0/s1 |
UTKJZGYXPDLBQS-STAGDXQRSA-N |
C[C@@H]1O[C@@H](O[C@H]2[C@@H](O[C@H](CO)[C@H](O)[C@@H]2O[C@H]2O[C@H](CO)[C@H](O)[C@H](O)[C@H]2O)O[C@H]2[C@H](O)[C@@H](CO)O[C@@H](O)[C@@H]2NC(C)=O)[C@@H](O)[C@H](O)[C@@H]1O |
|
epitope
The biological role played by a material entity when bound by a receptor of the adaptive immune system. Specific site on an antigen to which an antibody binds.
|
|
α-L-fucopyranosyl-(1→2)-[α-D-galactopyranosyl-(1→3)]-β-D-galactopyranosyl-(1→3)-2-acetamido-2-deoxy-β-D-glucopyranose
|
6-deoxy-α-L-galactopyranosyl-(1→2)-[α-D-galactopyranosyl-(1→3)]-β-D-galactopyranosyl-(1→3)-2-acetamido-2-deoxy-β-D-glucopyranose
|
IUPAC
|
α-D-Gal-(1→3)-[α-L-Fuc-(1→2)]-β-D-Gal-(1→3)-β-D-GlcNAc
|
ChEBI
|
α-D-galactosyl-(1→3)-[α-L-fucosyl-(1→2)]-β-D-galactosyl-(1→3)-N-acetyl-β-D-glucosamine
|
ChEBI
|
α-L-Fuc-(1→2)-[α-D-Gal-(1→3)]-β-D-Gal-(1→3)-β-D-GlcNAc
|
ChEBI
|
α-L-fucosyl-(1→2)-[α-D-galactosyl-(1→3)]-β-D-galactosyl-(1→3)-N-acetyl-β-D-glucosamine
|
ChEBI
|
α-L-Fucp-(1→2)-[α-D-Galp-(1→3)]-β-D-Galp-(1→3)-β-D-GlcpNAc
|
ChEBI
|
αFuc1-2(αGal1-3)βGal1-3βGlcNAc
|
ChEBI
|
αGal1-3(αFuc1-2)βGal1-3βGlcNAc
|
ChEBI
|
β-D-glucopyranose, O-6-deoxy-α-L-galactopyranosyl-(1→2)-O-[α-D-galactopyranosyl-(1→3)]-O-β-D-galactopyranosyl-(1→3)-2-(acetylamino)-2-deoxy-
|
ChEBI
|
blood group B type 1 tetrasaccharide
|
ChEBI
|
Fucα1-2(Galα1-3)Galβ1-3GlcNAcβ
|
ChEBI
|
Gala1-3(Fuca1-2)Galb1-3GlcNAcb
|
ChEBI
|
Galα1,3(Fucα1,2)Galβ1,3GlcNAcβ
|
ChEBI
|
Galα1-3(Fucα1-2)Galβ1-3GlcNAcβ
|
ChEBI
|
O-6-deoxy-α-L-galactopyranosyl-(1→2)-O-[α-D-galactopyranosyl-(1→3)]-O-β-D-galactopyranosyl-(1→3)-2-(acetylamino)-2-deoxy-β-D-glucopyranose
|
ChEBI
|
WURCS=2.0/4,4,3/[a2122h-1b_1-5_2*NCC/3=O][a2112h-1b_1-5][a1221m-1a_1-5][a2112h-1a_1-5]/1-2-3-4/a3-b1_b2-c1_b3-d1
|
GlyTouCan
|